G. Steven Burrill To Head Biotechnology Advisory Council

SAN FRANCISCO, Calif., Sept. 27 /PRNewswire/ -- G. Steven Burrill, CEO of life sciences merchant bank Burrill & Company, and a 30+ year veteran of the Bay Area biotech community has been named Chairman of the newly formed San Francisco Mayor's Biotechnology Advisory Council (MayBAC). Burrill has been working for San Francisco Mayor Gavin Newsom to create this new advisory council, which will foster the growth of the biotech industry in the city and county of San Francisco. "MayBAC will serve both as a stimulus and a magnet to attract talent, acumen, and capital to San Francisco and to advise the City and County of San Francisco on policy matters which are important to the development of biotech jobs in San Francisco," said G. Steven Burrill.

"The biotech industry was born here in the Bay Area some 30+ years ago, based on powerful science emanating from UCSF, Stanford, UC Berkeley, and UC Davis. Indeed, many view the Bay Area as the "mother church" of biotech. The list of the MayBAC advisory board members reads like a who's who of industry pioneers," noted Burrill. "Most of these seasoned individuals have been part of the development of the biotech industry since its start in the late 60's/early 70's and they will be using their collective expertise to help with policy matters, encourage biotech growth in San Francisco and work to expand the biotech job market in San Francisco," he said.

"Although today there are more than 800 biotech companies in the Bay Area, the opening of the new Mission Bay campus of UCSF and the tremendous talent and knowledge emanating both from academia and industry provides San Francisco with a unique opportunity which the Mayor intends to capitalize upon," said Burrill. "Together we have recruited a dozen of the city's wisest and most successful industry veterans to guide government leaders in their efforts to forge an enticing business development strategy and to be the city's ambassadors to the broader biotech world," Burrill explained.

The MayBAC is comprised of industry executives and academic leaders including:

Chairman G. Steven Burrill, CEO, Burrill & Company Biotech Advisory Council Members Brook Byers, Partner, Kleiner Perkins Caufield & Byers Bill Rutter, Co-Founder and Former Chairman, Chiron Gail Maderis, CEO, Five Prime Therapeutics Joel Marcus, CEO, Alexandria Real Estate Equities Fred Dorey, Attorney, Cooley Godward Bruce Jenett, Partner, Heller Ehrman Mike Bishop, Chancellor, University of California, San Francisco James Sabry, President and CEO, Cytokinetics David Goddell, Vice President Research, Amgen Sue Desmond-Hellman, President, Product Development, Genentech Phillip Day, Chancellor, City College of San Francisco Robert Corrigan, Chancellor, San Francisco State University About Burrill & Company

Burrill & Company is a life sciences merchant bank, focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, human healthcare and related medical technologies, wellness and Nutraceuticals, agricultural technologies, and industrial biotechnology (biomaterials/bioprocesses).

Venture Capital

The Burrill family of venture capital funds, with over $500 million under management, includes the Burrill Life Sciences Capital Fund, the Burrill Biotechnology Capital Fund, the Burrill Agbio Capital Fund and its successor -- the Burrill Agbio Capital Fund II, and the Burrill Nutraceuticals Capital Fund.

Strategic Partnering

Burrill & Company assists life science companies in identifying, negotiating and closing strategic partnerships between large and small companies in providing access to resources, technologies or collaborations essential for executing their business plans.

Burrill & Company also works with major life science companies to spinout internal assets and capitalizes on their value, ranging from the outright sales of products or businesses to creation of new companies to exploit these assets. Burrill uses its extensive network to help companies identify, assess and capture ("spin-in") products and companies strategic to building their businesses.

We have completed more than 25 strategic partnerships with a value in excess of $1.5 billion.

Strategic Advisory Services

Burrill & Company works with leaders of life science companies of all sizes (from start-up to big Pharma) on growth strategy with a focus on how strategic transactions and partnerships can enable and accelerate the achievement of corporate objectives. We combine our scientific, business operations, financial and technical skill sets with an objective advisory approach. We then work with our external clients to implement these plans, whether it is to succeed through an M&A/partnering transaction or a financing, divestiture or a restructuring.

Biotech 2004/Burrill Datacenter

Burrill & Company's annual analysis of the "State of the Industry" has been an important part of the biotech industry's view of itself over the last 18 years. Biotech 2004-Life Sciences: Back on Track, is a perspective on where the industry has been and is going and was released Q1 04. In addition, the newly created Burrill Datacenter is an online resource for keeping up-to-date information from the biotech industry at your fingertips, including updated data from Biotech 2004. To order Biotech 2004 or to subscribe to the Burrill Datacenter, visit http://www.burrilldatacenter.com/ or call 415-591-5400.

Burrill & Company

CONTACT: Mandy Jones of Burrill & Company, +1-415-591-5405, or fax,+1-415-591-5401, or mandy@b-c.com

Back to news